Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;24(1):1700818.
doi: 10.2807/1560-7917.ES.2019.24.1.1700818.

Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16

Helen Findlow  1 , Helen Campbell  2 , Jay Lucidarme  3 , Nick Andrews  4 , Ezra Linley  1 , Shamez Ladhani  2 , Ray Borrow  1   3   5
Affiliations

Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16

Helen Findlow et al. Euro Surveill. 2019 Jan.

Abstract

BackgroundIn 1999, the United Kingdom (UK) was the first country to introduce meningococcal group C (MenC) conjugate vaccination. This vaccination programme has evolved with further understanding, new vaccines and changing disease epidemiology.AimTo characterise MenC disease and population protection against MenC disease in England.MethodsBetween 1998/99-2015/16, surveillance data from England for laboratory-confirmed MenC cases were collated; using the screening method, we updated vaccine effectiveness (VE) estimates. Typing data and genomes were obtained from the Meningitis Research Foundation Meningococcus Genome Library and PubMLST Neisseria database. Phylogenetic network analysis of MenC cc11 isolates was undertaken. We compared bactericidal antibody assay results using anonymised sera from 2014 to similar data from 1996-1999, 2000-2004 and 2009.ResultsMenC cases fell from 883 in 1998/99 (1.81/100,000 population) to 42 cases (0.08/100,000 population) in 2015/16. Lower VE over time since vaccination was observed after infant immunisation (p = 0.009) and a single dose at 1-4 years (p = 0.03). After vaccination at 5-18 years, high VE was sustained for ≥ 8 years; 95.0% (95% CI: 76.0- 99.5%). Only 25% (75/299) children aged 1-14 years were seroprotected against MenC disease in 2014. Recent case isolates mostly represented two cc11 strains.ConclusionHigh quality surveillance has furthered understanding of MenC vaccines and improved schedules, maximising population benefit. The UK programme provides high direct and indirect protection despite low levels of seroprotection in some age groups. High-resolution characterisation supports ongoing surveillance of distinct MenC cc11 lineages.

Keywords: Neisseria meningitidis; bacterial meningitis; epidemiology; immunisation; surveillance; vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Incidence rate of group C meningococcal disease by epidemiological year, England, 1998/99–2015/16
Figure 2
Figure 2
Clonal complex distribution among meningococcal serogroup C case isolates, England, 2010/11–2015/16
Figure 3
Figure 3
Diversity and temporal distribution of meningococcal serogroup C case isolates, England, 2010/11–2015/16
Figure 4
Figure 4
Seroprotection against serogroup C meningococci measured by proportions with serum bactericidal antibody (SBA) titres of ≥ 8
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R, Global Meningococcal Initiative Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14(4):505-17. 10.1586/14760584.2015.979799 - DOI - PubMed
    1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58-67. 10.1016/S0264-410X(01)00299-7 - DOI - PubMed
    1. Whittaker R, Dias JG, Ramliden M, Ködmön C, Economopoulou A, Beer N, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034-41. 10.1016/j.vaccine.2017.03.007 - DOI - PubMed
    1. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365-6. 10.1136/bmj.326.7385.365 - DOI - PMC - PubMed
    1. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840-7. 10.1128/CVI.00529-09 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources